Genedata, a Danaher company and a leading provider of enterprise software solutions for biopharmaceutical research and development, today announced that mAbxience has selected the Genedata Bioprocess® enterprise platform to structure and harmonize all bioprocess development data across its operations. mAbxience, majority-owned by the Fresenius Kabi Group, is a global contract development and manufacturing organization (CDMO) specializing in the production of biosimilars.
“As the biosimilar portfolio expands and the complexity of bioprocess development increases, we need a single integrated platform to connect and analyze all data across upstream, downstream, cell line, formulation, and analytical development.” Dr. Iván Sánchez de Mello, Research and Development Director, said: “Genedata Bioprocess, running on Genedata Cloud, automates our processes and ensures complete data integrity and traceability across all groups. This foundational system allows us to scale efficiently and prepare for the next step, process modeling, while meeting the global demand for high-quality biologics.”
By implementing Genedata Bioprocess as a SaaS solution, mAbxience gains an integrated digital backbone to track and automate end-to-end bioprocess workflows, enabling faster decision-making, streamlined collaboration, increased reproducibility, and documentation. This platform consolidates all experimental and process data into a single source of truth for all CDMO operations. This strategic move will enable mAbxience to improve operational efficiency and move towards AI-driven process optimization.
We are excited to welcome mAbxience to the Genedata community and further expand our footprint in the CDMO industry. By centralizing all data on one platform, mAbxience is taking a major step towards automation and data integrity, increasing AI maturity and responsiveness. This investment will ensure scalability, compliance and innovation in biosimilar manufacturing. We continue to invest in the Genedata platform to meet the needs of the rapidly growing CDMO industry. ”
Dr. Otmar Pfannes, President of Genedata
